Antibody-based therapeutics now include conventional monoclonal antibodies (mAbs), bispecific antibodies, antibody-drug conjugates (ADCs), and other engineered biologics. As molecular formats grow more complex, knowing where an antibody travels after administration, and whether it reaches the intended biological target, has become a recurring question in preclinical drug development.
Conventional pharmacokinetic (PK) studies measure antibody concentrations in plasma or serum. These measurements describe systemic exposure, clearance, and half-life, but they give limited information about how an antibody distributes across tissues.
Immuno-positron emission tomography (Immuno-PET) addresses part of this gap. By radiolabeling an antibody or an antibody-derived targeting probe, PET can visualize and quantify its distribution across the body across multiple time points. When the tracer retains target-binding properties, the imaging data can describe tissue accessibility, target-associated uptake, and the relationship between systemic exposure and tissue distribution.
The measurement itself is straightforward in principle. A positron-emitting radionuclide decays inside the body, the emitted positron annihilates with a nearby electron, and the detector ring records the pair of photons that leaves the subject in opposite directions. Reconstructing many such events produces a three-dimensional map of activity concentration, which can be followed in the same animal for as long as the radionuclide's half-life allows.
In non-human primates (NHPs), Immuno-PET is well-suited because molecular imaging can be combined with plasma PK, anatomical imaging, tissue biomarkers, and pharmacodynamic endpoints within a single translational study.
The question is not only where the antibody goes, but whether it reaches the intended tissue, engages the relevant target, and produces a distribution consistent with its intended pharmacology.
Why Plasma PK Alone Does Not Describe Antibody Biodistribution
Plasma PK remains a core component of biologics development. Parameters such as Cmax, AUC, clearance, and half-life describe systemic exposure and support dose selection and exposure-response modeling.
However, systemic exposure does not necessarily predict tissue exposure. A plasma concentration curve is a lumped readout: it sums the contributions of every tissue that takes up antibody and returns it to circulation, and the shape of the curve therefore reflects the whole body rather than any single organ.
An antibody can remain in circulation for an extended period while exhibiting very different uptake profiles across organs. Target expression, vascular permeability, tissue architecture, Fc receptor interactions, antigen-mediated internalization, and nonspecific uptake can each shape tissue distribution.
This creates a distinction between systemic PK and tissue-level pharmacology.
For an antibody therapeutic, several questions often remain open after conventional PK analysis:
- Does the antibody reach the target tissue?
- Is the molecular target accessible to the antibody in vivo?
- Does target expression vary between tissues or lesions?
- Is uptake primarily target-mediated or nonspecific?
- Does high target expression in normal tissues affect distribution?
- How does tissue uptake change over time?
Terminal tissue sampling answers some of these, but usually at a few selected time points and in a limited set of tissues. Each animal contributes one snapshot per organ, and the number of snapshots is bounded by the number of animals in the study. Immuno-PET adds a longitudinal, non-invasive perspective by tracking how a radiolabeled antibody or targeting probe distributes over time.
The gap matters most for biologics with long circulation times and complex tissue distribution patterns.
What Is Immuno-PET?
Immuno-PET combines the molecular recognition properties of antibodies with the sensitivity and quantitative capabilities of positron emission tomography. The antibody supplies the specificity; the camera supplies the sensitivity and the spatial readout.
In a typical study, a monoclonal antibody or antibody-derived probe is labeled with a positron-emitting radionuclide. For intact antibodies, longer-lived radionuclides such as zirconium-89 (89Zr) are commonly used because their physical half-life matches the relatively slow distribution and clearance kinetics of IgG molecules.
89Zr has a physical half-life of approximately 3.3 days, supporting imaging over several days after administration. This makes it useful for delayed tissue distribution studies, though the optimal radionuclide depends on the molecular format, biological kinetics, labeling chemistry, and study objective. Carmon and Azhdarinia's 2018 review notes that 89Zr is a frequently used radionuclide for antibody imaging because its half-life allows delayed imaging and assessment of antibody biodistribution over an extended window.
Labeling is a chemical step, not a neutral one. The chelator that holds the radiometal, the conjugation site, and the degree of substitution can all shift binding or clearance, so immunoreactivity and affinity are normally checked after labeling rather than assumed from the unconjugated batch.
A typical Immuno-PET workflow includes:
Antibody selection → Radiolabeling → Administration → Serial PET imaging → Anatomical co-registration → Quantitative analysis → Biodistribution and target-engagement interpretation
The imaging readout may include regional activity concentration, SUV, tissue-to-background ratios, time-activity curves, and other quantitative parameters. More advanced analyses can incorporate kinetic modeling or comparisons with plasma PK and ex vivo tissue measurements.
PET signal is not the same as the concentration of intact therapeutic antibody in tissue. Radiolabel metabolism, nonspecific uptake, blood-pool activity, tracer stability, and any differences between the imaging probe and the therapeutic molecule all need to be accounted for. Activity that sits in a region of interest can come from intact tracer bound to target, from labeled fragments, from free radiometal, or simply from blood in the vasculature of that region.
From Biodistribution to Target Accessibility
A practical advantage of Immuno-PET is that it moves the analysis beyond simple whole-body biodistribution.
For targeted antibodies, tissue uptake may reflect several overlapping processes:
Systemic circulation → Tissue delivery → Target accessibility → Antibody binding → Internalization or retention → Clearance
A high PET signal in a target tissue can indicate favorable delivery, but it does not by itself prove pharmacological target engagement.
To strengthen interpretation, Immuno-PET data can be combined with independent measurements such as receptor expression, tissue biomarkers, immunohistochemistry, ex vivo biodistribution, or receptor occupancy assays.
ADC programs rely on this layering of evidence in particular. An ADC depends on systemic exposure, target antigen accessibility, antibody binding, internalization, intracellular trafficking, and subsequent payload release. Imaging the antibody says something about the first four steps and very little about the last two, which is why payload-related readouts still have to come from other methods.
Carmon and Azhdarinia's 2018 review describes how 89Zr-immuno-PET has been used to evaluate whole-body biodistribution, pharmacokinetics, and tumor targeting of antibodies and ADCs. It also raises the possibility of using molecular imaging to characterize target heterogeneity and support patient-selection strategies.
Immuno-PET is most useful as a functional imaging approach that sits alongside molecular and histological measurements, not a standalone replacement for them.
Why NHP Models Add Translational Context
What Immuno-PET adds depends on the imaging technology and on the biological model used.
NHP studies offer a useful translational setting for antibody biodistribution because they support serial imaging together with conventional pharmacology, biomarker analysis, and, when scientifically justified, tissue sampling.
NHPs also allow imaging protocols closer to the scale and workflow of clinical PET studies than most smaller-animal models. Larger body size provides sufficient anatomical separation for organ-level imaging, and longitudinal imaging allows each animal to serve as its own reference across multiple time points. A whole-body scan of a mouse compresses several organs into a few voxels; in a macaque, the same reconstruction resolves them separately, and the acquisition and reconstruction steps resemble those used in patients.
The relevance of the NHP model still needs to be evaluated on a case-by-case basis. Cross-species differences in target expression, epitope recognition, Fc receptor interactions, and antibody pharmacology can influence how Immuno-PET data is interpreted.
For this reason, target cross-reactivity and binding characteristics should be confirmed in the chosen NHP species before using the model for quantitative target-specific imaging. A tracer that binds the human target but not the macaque ortholog will report perfusion and blood pool, and nothing about the antigen.
A biologically relevant NHP model is not simply one in which the antibody can be detected. It is one in which the molecular interaction being studied is sufficiently comparable to the intended clinical mechanism.
What Immuno-PET Can Add to Antibody Development
Characterizing Whole-Body Biodistribution
Serial PET imaging can map the relative distribution of a radiolabeled antibody across major organs and tissues, complementing plasma PK and conventional ex vivo biodistribution studies.
The resulting data can help distinguish expected physiological distribution from unusual accumulation and identify tissues that warrant additional investigation. Because the same animal is imaged repeatedly, a rising or falling signal in one organ can be separated from the between-animal variability that complicates comparison of single-time-point groups.
Evaluating Target Accessibility
For target-specific antibodies, imaging can indicate whether the target is accessible in vivo.
This differs from showing target expression in a tissue sample. Immunohistochemistry and similar ex vivo assays confirm presence, while Immuno-PET adds in vivo accessibility and antibody accumulation. A target can be abundant on a section and still be unreachable in a living animal if the vasculature supplying that tissue does not permit antibody extravasation.
Investigating Target Heterogeneity
Target expression may vary among tissues, lesions, or disease stages.
This matters most in oncology, where a single biopsy does not always represent target expression across lesions. Whole-body imaging can map target distribution across lesions in ways a single tissue sample cannot.
Supporting Antibody and ADC Selection
Different antibodies directed toward the same target may have different affinities, epitope recognition, internalization characteristics, or tissue distribution.
Immuno-PET can be incorporated into candidate-selection strategies by comparing tissue uptake and target-associated distribution before advancing a molecule into more resource-intensive development stages.
From Imaging PK to Target Engagement
Linking Immuno-PET to the broader imaging PK/PD framework matters for translational reasoning.
As discussed in the related article Imaging-Based PK/PD Assessment in Non-Human Primates, conventional plasma PK describes systemic exposure, while imaging adds spatial and longitudinal information about tissue distribution.
For antibody development, this relationship can be extended:
Plasma PK → Tissue Biodistribution → Target Accessibility → Target Engagement → Pharmacodynamic Response
Each step answers a different question. Plasma PK describes how much antibody is present in circulation. Imaging PK shows where the labeled antibody is distributed and how that distribution changes over time.
Target-specific Immuno-PET can provide evidence of target-associated uptake when the tracer and experimental design support such interpretation.
Pharmacodynamic measurements then determine whether target interaction translates into a measurable biological response.
This integrated framework is most useful for biologics whose therapeutic activity depends on tissue penetration or molecular target accessibility.
Important Methodological Considerations
Immuno-PET is a demanding methodology, and several technical factors need to be considered when designing and interpreting studies.
Tracer and Therapeutic Molecule Comparability
Radiolabeling can alter an antibody's biological behavior. The labeled tracer should be characterized for immunoreactivity, affinity, stability, and other relevant properties before use.
For ADC programs, an additional consideration is that the imaging antibody and the therapeutic ADC are not necessarily identical molecules. Conjugation of a payload can alter molecular properties, including pharmacokinetics and stability.
Consequently, biodistribution of a radiolabeled naked antibody should not automatically be assumed to be identical to the biodistribution of the corresponding ADC.
This limitation is documented in the Immuno-PET literature (e.g., Carmon and Azhdarinia, 2018) and deserves attention when imaging findings are translated into therapeutic conclusions.
Target-Mediated Drug Disposition
High target expression in normal tissues can substantially influence antibody distribution and clearance.
Target-mediated drug disposition (TMDD) describes this pattern: tissue-specific uptake that diverges from nonspecific distribution. When a target is present at high density on a tissue that is not the therapeutic target, that tissue can act as a sink, binding antibody, internalizing it, and removing it from circulation. Imaging can show the pattern, but quantitative interpretation requires appropriate pharmacological context.
Blood-Pool Activity
Because antibodies circulate for prolonged periods, vascular activity can dominate the PET signal at early imaging time points.
This is one reason longitudinal imaging and appropriate anatomical segmentation are important when interpreting tissue uptake. A region of interest drawn around a well-perfused organ at one hour after dosing largely measures blood; the same region at day four is more likely to report tissue.
Quantitative Imaging
SUV and tissue-to-background ratios are useful quantitative measures, but they do not necessarily provide a complete description of antibody kinetics. SUV normalizes activity to injected dose and body weight, which makes scans comparable across animals but says nothing about the shape of the uptake curve.
Depending on the research question, time-activity curves, kinetic modeling, plasma input functions, and ex vivo validation may provide additional information.
The appropriate quantitative method should be selected according to whether the primary objective is biodistribution, tissue kinetics, target binding, or pharmacodynamic assessment.
Integrating Immuno-PET With Multimodal NHP Research
Immuno-PET adds more when interpreted alongside other translational endpoints.
For example:
PET-CT can combine molecular signal with anatomical localization.
MRI can add soft-tissue and high-resolution anatomical information, particularly for CNS studies.
Plasma PK provides systemic exposure measurements.
Biomarkers and pathology offer independent evidence of biological activity or tissue effects.
Functional endpoints indicate whether molecular target engagement translates into a measurable pharmacological response.
Prisys' translational research infrastructure includes PET-CT, MRI, CT, DSA, and other clinical-equivalent imaging modalities, supporting multimodal imaging within NHP studies.
The broader platform also supports NHP pharmacology, PK/PD assessment, biomarker investigation, and target-engagement studies, so molecular imaging data can be interpreted within a wider preclinical research framework.
This integrated approach matters most when the development question extends beyond simple biodistribution:
Does the antibody reach the intended tissue, interact with its target, and produce the expected biological response?
Translational Applications in Antibody and ADC Development
Immuno-PET can be incorporated into different stages of biologics development. During early candidate selection, it can compare antibodies on tissue distribution and target-associated uptake. During preclinical pharmacology, it can complement plasma PK and tissue analysis to investigate exposure at relevant sites.
For ADC programs, it can inform target accessibility and whole-body distribution in ways that complement efficacy and safety studies.
For oncology programs, whole-body imaging can characterize heterogeneous target expression across lesions and support the development of imaging biomarkers.
Clinical reports also point to a role for Immuno-PET in patient selection and companion-diagnostic development, although translation from a preclinical imaging tracer to a clinical diagnostic requires separate validation. The ZEPHIR study is a well-known example: 89Zr-trastuzumab imaging was investigated in relation to treatment response in HER2-positive breast cancer.
For preclinical NHP programs, the immediate value is generally a more concrete understanding of antibody biodistribution, target accessibility, and exposure-response relationships before clinical translation.
Conclusion
The value of Immuno-PET in NHP research is not just the ability to visualize an antibody.
Its scientific value lies in connecting systemic exposure with spatial distribution and molecular target accessibility.
Conventional plasma PK remains essential for understanding systemic exposure. Ex vivo tissue analysis provides detailed information at selected anatomical sites. Immuno-PET adds a longitudinal, whole-body imaging dimension that can show where a radiolabeled antibody accumulates and how that distribution changes over time.
Combined with target-expression assays, tissue biomarkers, pathology, and pharmacodynamic endpoints, Immuno-PET contributes to a more integrated view of antibody pharmacology.
For NHP studies of mAbs, bispecific antibodies, and ADCs, a useful framework is therefore:
Exposure → Biodistribution → Target Accessibility → Target Engagement → Biological Response
This framework connects molecular imaging concepts discussed across the broader Prisys series, from PET biodistribution and imaging-based PK/PD to quantitative target engagement and translational molecular imaging.
The objective is not to replace conventional PK or tissue analysis, but to add spatial and longitudinal information that those methods cannot provide alone.
Carmon KS, Azhdarinia A. Application of Immuno-PET in Antibody-Drug Conjugate Development. Mol Imaging. 2018;17:1536012118801223. doi:10.1177/1536012118801223
FAQ
What is Immuno-PET?
A: Immuno-PET is a molecular imaging approach that uses radiolabeled antibodies or antibody-derived probes to visualize and quantify their distribution in vivo. It can provide information about tissue uptake, target accessibility, and, with appropriate study design, target-associated binding.
Why use Immuno-PET in NHP models?
A: NHP models allow serial molecular imaging to be integrated with plasma PK, anatomical imaging, biomarkers, and pharmacological endpoints in a physiologically relevant large-animal model. This can provide complementary information about systemic exposure and tissue distribution.
Why is 89Zr commonly used for antibody Immuno-PET?
A: 89Zr has a physical half-life of approximately 3.3 days, which is compatible with the relatively slow distribution and clearance kinetics of many intact antibodies. It can therefore support delayed imaging over several days.
Does Immuno-PET directly measure therapeutic antibody concentration?
A: Not necessarily. PET measures radioactive signal from the labeled tracer. Interpretation depends on tracer stability, metabolism, blood-pool activity, nonspecific uptake, and the relationship between the imaging tracer and the therapeutic molecule.
Can Immuno-PET demonstrate target engagement?
A: It can provide evidence of target-associated uptake when the tracer has appropriate target specificity and the study includes suitable controls and quantitative analysis. However, PET findings are generally interpreted together with independent target-expression, receptor-occupancy, or pharmacodynamic measurements.
